Clinical outcomes of relapsed refractory acute myeloid luekemia patients treated with venetoclax combination therapy and to analyze molecular predictors of these outcomes
Latest Information Update: 22 Jan 2021
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 22 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology